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Abstract 
Background: Peritoneal protein excretion (PPE) is a potential marker of the outcome in peritoneal dialysis (PD) 
patients. Method: Observational study of a cohort of 269 patients starting PD in a single unit. Study variables: total 
PPE during a baseline peritoneal equilibration test (PET; PET-PPE) and 24-hour PPE. Control variables: essential 
baseline demographic, laboratory and adequacy markers. Main outcomes: mortality, cardiovascular events and risk of 
peritonitis. We applied univariate and multivariate strategies of survival analysis. Main Results: PET-PPE sustained a 
significant, yet limited correlation with 24-hour PPE (r = 0.46, p < 0.0005). At baseline, the main study variables 
showed an independent correlation with peritoneal transport characteristics (D/P240’ creatinine) and cardiovascular 
comorbidity. PET-PPE (p < 0.0005, model global χ2 59.4) was a more accurate predictor of overall mortality than 24-
hour PPE (p = 0.04, χ2 50.5). Moreover, PPE during PET, but not 24-hour PPE, was an independent predictor of the 
risks of cardiovascular and infectious mortality, and of peritonitis. Conclusions: Baseline PPE represents a strong 
independent marker of survival of PD patients. Estimation of PPE during PET is more accurate than 24-hour PPE for 
this purpose, sustains a definite independent association with cardiovascular and infectious mortality, and shows a 
significant correlation with the risk of peritonitis. 
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Peritoneal protein excretion (PPE) is universally viewed as an adverse effect of peritoneal dialysis 
(PD). It plays an ill-defined role in the genesis of malnutrition of these patients [1] and may contribute, to 
a variable degree, to several disorders observed in PD patients, including dyslipemia, hormonal 
disturbances and a prothrombotic environment [2–6].  
 
Peritoneal transport of proteins occurs essentially through large intercellular pores, and is limited by 
size rather than charge restriction [7–10]. Several studies have suggested that the functionality of these 
pores may be affected by endothelial disorders and inflammatory states [11, 12]. This raises the 
possibility that PPE may operate as a marker of large-pore dysfunction, indicating endothelial disease, 
inflammation and, eventually, cardiovascular (CV) risk for PD patients [11]. In the last few years, several 
studies have focused on the potential clinical significance of this hypothesis, using 24-hour PPE as a 
marker of this phenomenon [11, 13–15].  
 
The peritoneal equilibration test (PET) is the standard procedure for the categorization of peritoneal 
transport characteristics in clinical practice [16]. As such, it is focused on the behavior of small solutes, 
including creatinine and glucose. However, it can also be used to categorize the peritoneal transport of 
different proteins [7, 16–18]. We have recently shown that the PET permits a standardized and 
reproducible assessment of the peritoneal transport of total proteins, seemingly providing a more focused 
view of this phenomenon than analysis of 24-hour PPE [19]. We present the results of a study aimed to 
compare the accuracy of both approaches to categorize the overall risk of a wide cohort of patients 
starting chronic PD therapy in a single center.  
Population and Method  
General Design  
We analyzed a historic cohort of patients starting PD in a single unit (University Hospital of A 
Coruña, Spain) between January 2000 and December 2008. Follow-up was finished by May 31, 2009. 
The main objective of the study was to analyze the ability of PPE estimated from baseline 24-hour or PET 
dialysate collections to predict the outcome of these patients. We applied a multivariate strategy of 
analysis to control for factors known to have a significant impact on general prognosis during PD therapy. 
The study protocol fulfilled the ethical requirements for noninterventional retrospective cohort studies 
demanded by our institution.  
Population  
For analysis, we included all patients starting PD during the above-mentioned period who fulfilled 
two conditions: minimal follow-up of two months without peritonitis, and baseline (≤ 2 months since 
initiation of PD) estimation of PPE in both 24-hour and PET dialysate collections. 286 patients were 
scrutinized, but 17 patients were excluded from analysis due to death or discontinuing PD after less than 2 
months of follow-up (n = 10), baseline 24-hour PPE and/or PET-PPE not available (n = 6) or inadequate 
clinical records (n = 1). Table 1 depicts the main clinical characteristics of the final study population at 
the inception of PD therapy. All patients used lactate-based solutions for routine PD, while 56 patients on 
CAPD (34.4%) and 71 on automated PD (67.0%) had icodextrin for the long dwell at the time of the 
baseline sample collection.  
  
Table 1. Study population: baseline clinical characteristics 
  
Age, years  57.3 ± 16.1 (8, 87) 
Gender, males/females (%)  167/102 (62.1/37.9) 
Underlying renal disease  
Chronic glomerulonephritis 33 (12.3) 
Vascular 20 (7.4) 
Interstitial 23 (8.6) 
Cystic 23 (8.6) 
Diabetic nephropathy 74 (27.5) 
Systemic 12 (4.4) 
Other unknown 84 (31.3) 
PD modality, CAPD/automated PD (%)  163/106 (60.6/39.4) 
Diabetes (%)  98 (36.4) 
Baseline cardiovascular comorbidities  
Ischemic heart disease  63 (23.1) 
Stroke  30 (11.1) 
Peripheral arterial disease  32 (11.9) 
Major arrhythmia  28 (10.4) 
Heart failure  55 (20.4) 
Other heart diseases  35 (13.1) 
Patients with at least one cardiovascular comorbidity  130 (48.3) 
Baseline noncardiovascular comorbidities  
Pulmonary disease  21 (7.8) 
Liver disease  23 (8.6) 
Neoplasia  21 (7.8) 
Major depression  23 (8.6) 
Charlson’s comorbidity score  3.91 ± 1.89 (2, 9) 
Cardiovascular comorbidity score  1.42 ± 1.83 (0, 7) 
Systolic blood pressure, mm Hg  137.2 ± 17.8 (80, 195) 
Diastolic blood pressure, mm Hg  79.1 ± 10.9 (45, 105) 
Number of antihypertensive drugs  1.45 ± 0.96 (0, 5) 
Malnutrition, any degree (Subjective Global Assessment)  34 (12.6) 
BMI  25.9 ± 4.6 (15.4, 43.5) 
  
 
Numerical variables presented as mean values ± SD (range). 
Categorical variables presented as n (%). 
Study Variables  
We recorded the baseline clinical characteristics of patients at baseline (table 1). The modality of PD 
was computed according to the status of the patient at the end of the second month of follow-up. Baseline 
comorbidity was categorized in two different ways. The Charlson’s comorbidity score was used as a 
control variable for general outcomes, while for CV outcomes, we only applied CV comorbidity as a 
control variable. For this purpose, we created a CV comorbidity score, which was gained from the 
arithmetic addition of the accumulated CV comorbities with a correction factor for severity (0 = absent; 1 
= uncomplicated, i.e. medical management and no patent sequelae; 2 = complicated, i.e. invasive 
measures required or significant sequelae after event). Age was managed as an independent control 
variable, aside from Charlson’s score. Blood pressure was estimated from mean values recorded during 
the second month of home PD therapy. Malnutrition was diagnosed by standard Subjective Global 
Assessment, performed routinely at the start of PD therapy in our unit. It was managed as a binary 
variable, due to the extremely low baseline prevalence of severe malnutrition in the cohort. Body mass 






Table 2 presents the baseline control laboratory and adequacy variables. Glomerular filtration rate 
(GFR) was computed as the mean of urea and creatinine clearances. Daily ultrafiltration was obtained 
from the clinical records of the patients, and computed as the mean value during the second month of 
therapy. A standard PET with 2 liters of 2.27% glucose-based, lactate-buffered dialysate was performed 
in all patients during their second month on PD. We used D/P of creatinine at 240’ (D/P 240’ creatinine) as 
the surrogate of peritoneal transport characteristics. All the study variables presented in tables 1 and 2 
were available for analysis in > 95% of the patients.  
  
Table 2. Study population: baseline laboratory and adequacy data 
  
Plasma albumin, g/l  35.9 ± 5.6 (14, 48) 
Plasma cholesterol, mg/dl  171.5 ± 56.1 (71, 527) 
Hemoglobin, g/dl  11.0 ± 1.6 (5.1, 15.3) 
C-reactive protein, mg/l  5.6 (1.0, 167.0) 
Diuresis, ml/day  1,290 ± 633 (0, 3,400) 
Glomerular filtration rate, ml/min  6.94 ± 3.39 (0, 16.3) 
Total Kt/V  2.56 ± 0.71 (1.05, 4.55) 
Ultrafiltration on PD, ml/day  622 ± 550 (–600, 2,200) 
D/P240’ of creatinine, PET  0.66 ± 0.15 (0.31, 1.00) 
24-hour PPE, mg  5,576 ± 2,370 (600, 19,400) 
24-hour peritoneal protein clearance, ml  76.6 ± 39.2 (16.7, 403.4) 
Total dialysate protein content: overnight dwell, mg  2,332 ± 1,437 (240, 11,080) 
Overnight peritoneal protein clearance, ml  31.6 ± 20.4 (5.0, 165.6) 
Total dialysate protein content: PET, mg  1,14 ± 8540 (140, 3,690) 
Peritoneal protein clearance during PET, ml  15.7 ± 8.1 (3.9, 54.4) 
  
 
Numerical variables presented as mean values ± SD (range), except C-reactive protein, 
presented as the median (range). 
The main study variables were scrutinized for total protein excretion (24-hour PPE and PET-PPE) and 
total protein clearance (PCl; 24-hour PCl and PET-PCl). Twenty-four-hour PPE was estimated from a full 
24-hour dialysate collection for adequacy during the second month on PD, with a median time lapse 
versus PET of 7 days (range 0, 26). PET-PPE was computed as the total amount of protein in dialysate at 
the end of the baseline PET. Peritoneal protein clearance was estimated from the formulas PET-
PPE/(serum albumin/0.4783) (PET-PCl) and 24-hour PPE/(serum albumin/ 0.4783) (24-hour PCl) [20]. 
 
The main outcome variables scrutinized included mortality (overall, CV and infectious), CV 
morbidity (estimated from CV events demanding hospital admission) and PD-related peritonitis. In 
patients with several coexistent causes of death, mortality was assigned to that quoted as the main one at 
the time of demise.  
Laboratory Methods 
Blood levels of hemoglobin, glucose, urea, creatinine, albumin and cholesterol were quantified with a 
standard autoanalyzer (Advia 2400; Bayer®). Dialysate levels of glucose and creatinine, and urine levels 
of urea and creatinine, were estimated with adapted software from the same autoanalyzer. We corrected 
dialysate creatinine levels for simultaneous glucose levels. Plasma C-reactive protein was estimated using 
an immunoturbidimetric assay (Roche Diagnostics, Mannheim, Germany).  
 
A modified colorimetric assay (pirogalol red) was used for estimation of urine and dialysate total 
protein content. We have shown in a previous study [19] that this method is accurate and not affected by 
high concentrations of glucose in dialysate.  
Strategy of Analysis  
Data analysis was carried out following two main steps. First, we attempted to disclose correlations 
between the main study variables (PET-PPE/PCl and 24-hour PPE/PCl) on one side, and the clinical and 
laboratory markers scrutinized on the other. Secondly, we searched for the specific prognostic 
significance of the main study variables. For the univariate approach, we categorized the latter binarily 
(above/below the corresponding median values). Then we applied a multivariate strategy to obtain an 
adjusted effect for each study variable on each selected outcome. To avoid colinearity, serum albumin 
was excluded from PCl models. Comparisons between the efficiency of PET-PPE/PCl and 24- hour 
PPE/PCl as prognostic markers were based on the consistency of each variable to predict outcomes and 
the overall quality of the final models (global χ2 value).  
  
Statistics  
Numerical variables are presented as the mean ± SD or median values (range), as appropriate. 
Univariate comparisons between variables were produced according to Student’s t test, ANOVA, Mann-
Whitney and Wilcoxon tests (numerical), and χ2 distribution (categorical). We calculated correlations 
between numerical variables from Spearman’s correlation coefficient. Multivariate baseline correlates of 
PPE were assessed by stepwise multiple regression analysis. Univariate survival analysis was based on 
Kaplan-Meier’s method (comparisons log-rank test). Multivariate survival analysis was based on the Cox 
proportional hazards model. Cases were censored at recovery of renal function, switch to hemodialysis, 
loss to follow-up or renal transplant. We used SPSS 17.0 for data processing.  
Results 
Overview 
Tables 1 and 2 depict the main baseline clinical, laboratory and adequacy variables scrutinized. Table 
3 details the clinical outcomes of the whole cohort. Thirty-two percent of the patients suffered at least one 
CV event, and 36% of the patients died during follow-up. CV disease was the main cause of death, but 
infection, failure to thrive and miscellaneous causes also made up a significant proportion of deaths.  
Table 3. Main clinical outcomes 
  
Follow-up, months  29.0 ± 17.5 (2, 96) 
Cardiovascular events during follow-up  
Ischemic heart disease (29 patients) 39 (10.8) 
Stroke (11 patients) 13 (4.1) 
Peripheral vasculopathy (32 patients) 45 (11.9) 
Heart failure (24 patients) 42 (8.9) 
Other cardiovascular events (14 patients) 16 (5.2) 
Events – patients with at least one event (86 patients) 155 (32.0) 
Peritonitis (n/patient)  1.11 ± 1.52 (0, 8) 
Drop-out to hemodialysis 32 (12.9) 
Inadequacy/ultrafiltration failure 8 (3.0) 
Peritonitis 10 (3.7) 
Other 14 (5.2) 
Deaths 97 (36.0) 
Cardiovascular 43 (16.0) 
Myocardial infarction 10 
Heart failure 3 
Sudden death 12 
Mesenteric thrombosis 2 
Peripheral vasculopathy 9 
Stroke 3 
Other 4 
Infection 21 (7.8) 
Peritonitis 9 
Other infections 12 
Failure to thrive – withdrawal from dialysis 13 (4.8) 
Neoplasia 6 (2.2) 
Other 14 (5.2) 
Other 140 (52.0) 
Renal transplantation 71 (26.4) 
Active on PD at end of follow-up 60 (22.3) 
Lost to follow-up 6 (2.2) 
Recovery of renal function – PD suspended 3 (1.1) 
  
 
Numerical variables presented as mean values ± SD (range). Categorical 
variables presented as n (%). 
  
Analysis of both total PPE (overall r value 0.46, p < 0.0005; fig. 1) and PCl (r = 0.50, p < 0.0005) 
showed a significant correlation between PET and the 24-hour sample collection. However, the 
correlation was limited, indicating that both methods of estimation were not interchangeable. For 
instance, by setting an arbitrary limit at the mean + 1 SD, 58 patients were quoted as high protein 
transporters by either PET-PPE or 24-hour PPE, and only 12 (20.7%) were categorized as such by both 
methods (Kappa = 0.24). Interestingly, the correlation between both estimations was lower for automated 




Fig. 1. Correlation between PPE assessed from baseline PETs and 24-hour 
dialysate collections. 
Correlates of PPE  
Table 4 shows the most important univariate correlates of the main study variables. PET-PCl and 24-
hour PCl displayed overall similar coefficients compared to PET-PPE and 24-hour-PPE, respectively (not 
represented). There were clear trends to an association between both variables on one side and D/P 240’ of 
creatinine and markers of CV disease (diabetes, comorbidity scores) on the other. Multiple regression 
analysis disclosed D/P 240’ of creatinine (B = 9.53; 95% CI 5.36, 13.69; p < 0.0005), presence of diabetes 
mellitus (B = 1.97; 95% CI 0.54, 3.41; p = 0.007), the CV comorbidity score (B = 0.32; 95% CI 0.03, 
0.68; p = 0.043) and systolic blood pressure (B = 0.04; 95% CI –0.001, 0.07; p = 0.057) as independent 
predictors of PET-PPE (model r
2
 0.21). On the other side, only D/P 240’ of creatinine (B = 22.74; 95% CI 
4.36, 42.11; p = 0.002) and the CV comorbidity score (B = 1.80; 95% CI 0.16, 3.43; p = 0.031) showed 




Table 4. Main univariate correlates of PPE 
 PPE during PET 24-hour PPE 
   
Age  0.07 (0.26)  0.09 (0.15) 
Diabetes  0.17 (0.01)  0.11 (0.10) 
Gender  –0.006 (0.92)  –0.096 (0.12) 
Mode of PD  –0.03 (0.62)  –0.04 (0.48) 
Charlson’s score  0.22 (0.0005)  0.16 (0.011) 
CV comorbidity score  0.19 (0.002)  0.17 (0.006) 
Systolic blood pressure  0.11 (0.11)  0.09 (0.13) 
Diastolic blood pressure  –0.06 (0.30)  –0.01 (0.92) 
BMI  0.05 (0.39)  0.10 (0.11) 
Malnutrition (SGA)  0.07 (0.25)  0.03 (0.63) 
Plasma albumin  –0.003 (0.97)  –0.038 (0.54) 
Cholesterol  –0.10 (0.12)  –0.13 (0.042) 
Hemoglobin  –0.13 (0.035)  –0.06 (0.33) 
C-reactive protein  0.04 (0.55)  0.16 (0.008) 
Glomerular filtration rate  –0.01 (0.86)  0.02 (0.80) 
Kt/V  –0.07 (0.25)  0.02 (0.72) 
D/P240’ creatinine  0.31 (0.0005)  0.21 (0.0005) 
   
 
Figures denote Spearman’s correlation coefficients (p value). 
Association between PPE and Clinical Outcomes:Univariate Analysis 
Figure 2 shows that PET-PPE is a significant univariate predictor of overall survival of PD patients 
(fig. 2a). Twenty- four-hour PPE (fig. 2b), however, did not show such a capacity of discrimination. 
Interestingly, the predictive capacity of PET-PPE seemed to include both CV (fig. 3a) and infectious (fig. 




Fig. 2. Kaplan-Meier plot of overall survival risk according to PPE assessed from baseline PET (a) and 24-hour dialysate collection 





Fig. 3. Kaplan-Meier plot of CV mortality risk according to PPE assessed from baseline PET ( a ) and 24-hour dialysate collection ( 




Fig. 4. Kaplan-Meier plot of infectious mortality risk according to PPE assessed from baseline PET (a) and 24-hour dialysate 
collection (b). 1,030.9 mg (a) and 5.2 g (b) represent median values. 
We observed no univariate correlation between PETPPE or 24-hour PPE on one side, and survival to 
the first CV event on the other. The number of CV events during follow-up did not show any univariate 
association with the main study variables.  
 
We observed a nonsignificant trend to a lower survival to the first episode of peritonitis among 
patients above the median value of PET-PPE (fig. 5a), without differences related to 24-hour PPE (fig. 
5b). The incidence of peritonitis was similar according to PET-PPE (0.50 vs. 0.56 episodes/patient/year 
below/above median, p = 0.54) and 24-hour PPE (0.58 vs. 0.47 episodes/patient/year, respectively, p = 
0.14).  
 
Use of PET-PCl or 24-hour PCl yielded very similar results to PET-PPE and 24-hour PPE, 





Fig. 5. Kaplan-Meier plot of survival to the first episode of peritonitis according to PPE assessed from baseline PET (a) and 24-hour 
dialysate collection (b). 1030.9 mg (a) and 5.2 g (b) represent median values. 
Association between PPE and Clinical Outcomes: Multivariate Analysis  
Tables 5 and 6 show the main results of multivariate analysis. Overall peritoneal transport 
characteristics (as estimated by D/P 240’ creatinine) did not show a correlation with any of the outcome 
variables scrutinized. On the contrary, both PET-PPE/PCl and 24-hour PPE/PCl behaved as independent 
predictors of overall survival, after controlling for other significant covariates (table 5). PET-PPE/PCl 
was clearly a more powerful predictor of outcome than 24-hour PPE/PCl, permitting a more accurate 
global model. We detected significant interaction terms between C-reactive protein and Charlson’s score 
in both the PET-PPE/PCl and the 24-hour PPE/PCl models, but they did not significantly affect the 
coefficients for the main study variables. We also found a moderate interaction between age and 24-hour 
PPE/PCl (p = 0.043/0.049), suggesting that the latter variable was more predictive of an adverse outcome 
in younger patients. We ignored this interaction in the presentation of the models for better clarity (table 
5). 
Table 5. Correlation between overall mortality and different markers of PPE: multivariate analysis 
Covariables  HR 95% CI p Wald Model χ2 
      
PPE during PET, 100 mg 1.07 1.03, 1.12 0.0005 12.02 59.4 
Age, years 1.04 1.02, 1.06 0.0005 15.46  
Charlson’s score, points 1.13 1.01, 1.27 0.039 5.33  
Plasma albumin, g/l 0.93 0.89, 0.97 0.0005 12.56  
C-reactive protein, mg/l 1.09 1.00, 1.21 0.05 3.83  
Glomerular filtration rate, ml/min 0.95 0.90, 1.00 0.07 3.13  
PCl during PET, 10 ml 1.75 1.37, 2.23 0.0005 17.27 50.3 
Age, years 1.04 1.02, 1.07 0.0005 15.46  
Charlson’s score, points 1.17 1.04, 1.31 0.039 5.33  
C-reactive protein, mg/l 1.09 1.00, 1.21 0.05 3.83  
24-hour PPE, 500 mg 1.04 1.00, 1.08 0.04 4.04 50.5 
Age, years 1.07 1.02, 1.06 0.0005 14.19  
Charlson’s score, points 1.15 1.03, 1.28 0.019 5.55  
Plasma albumin, g/l 0.93 0.90, 0.97 0.003 9.68  
Glomerular filtration rate, ml/min 0.95 0.90, 0.99 0.041 3.95  
24-hour PCl, 10 ml 1.06 1.02, 1.11 0.01 6.71 38.0 
Age, years 1.04 1.02, 1.06 0.0005 14.11  
Charlson’s score, points 1.20 1.08, 1.34 0.001 10.77  
Glomerular filtration rate, ml/min 0.95 0.89, 1.00 0.055 3.75  
      
 
Cox’s proportional hazards models. Best model. 
 
  
Table 6. Other outcome correlates of peritoneal protein excretion: multivariate analysis 
Dependent variables  HR  95% CI  p  Wald  Model χ2  
Covariates in 
best model 
       
Cardiovascular mortality       
PPE during PET, 100 mg 1.09 1.03, 1.15 0.004 8.34 39.7 age 
PET-PCl, 10 ml 1.76 1.22, 2.55 0.002 9.15 32.0 diabetes 
24-hour PPE, 500 mg 1.01 0.95, 1.09 0.69 0.32 31.2 CV score 
24-hour PCl, 10 ml 1.04 0.94, 1.12 0.54 0.38 22.5 albumin 
First cardiovascular event       
PPE during PET, 100 mg 1.02 0.96, 1.06 0.71 0.24 36.7 age 
PET-PCl, 10 ml 1.31 0.91, 1.88 0.14 21.7 30.3 diabetes 
24-hour PPE, 500 mg 1.00 0.95, 1.05 0.85 0.44 31.3 CV score 
24-hour PCl, 10 ml 0.97 0.89, 1.05 0.04 0.60 30.4 albumin 
Infectious mortality       
PPE during PET, 100 mg 1.12 1.04, 1.21 0.006 6.32 21.7 age 
PET-PCl, 10 ml 2.00 1.17, 3.43 0.01 6.40 18.6 diabetes 
24-hour PPE, 500 mg 1.03 0.93, 1.14 0.56 0.60 15.5  
24-hour PCl, 10 ml 1.06 0.96, 1.17 0.25 1.34 11.7  
First peritonitis       
PPE during PET, 100 mg 1.04 1.00, 1.07 0.037 4.35 19.4 age 
PET-PCl, 10 ml 1.37 1.12, 1.68 0.02 10.63 19.1 mode of PD 
24-hour PPE, 500 mg 1.00 0.97, 1.04 0.86 0.04 15.0 CRP 
24-hour PCl, 10 ml 1.03 0.99, 1.07 0.17 2.13 15.1  
       
 
Cox’s proportional hazards models. CRP = C-reactive protein. 
Both CV and infectious mortality were independently and individually predicted by PET-PPE/PCl, 
but not by 24-hour PPE/PCl (table 6). The same applied for survival to the first episode of peritonitis. No 
interaction terms were detected for any of these models. Finally, neither PET-PPE/PCl or 24-hour 
PPE/PCl were independently predictive of survival to the first CV event (table 6).  
Discussion 
Our study confirms previous reports [11, 13–15] indicating that PPE is an independent predictor of 
survival in patients starting PD therapy. There are several potential explanations for this correlation. First, 
protein depletion may impact negatively on the nutritional state of these patients [1]. For years, this was 
the main concern associated with this side effect of PD. The apparent inverse correlation between PPE 
and serum albumin levels seemed to support this notion. Current knowledge indicates that this association 
is actually more complex, implicating other factors such as peritoneal membrane transport characteristics, 
endothelial dysfunction, inflammation, volume overload, etc. [11, 21–29]. The specific nutritional impact 
of the peritoneal protein leak in PD patients is currently unclear. On the other hand, depletion of specific 
proteins may contribute to a series of disorders observed in PD patients, including dyslipidemia, 
hormonal disturbances and a prothrombotic environment [2–6]. It is also conceivable that the immune 
competence of these patients may be compromised by the continuous leak of immunoactive proteins. 
More recently, several studies have provided a different insight into the question, by contemplating PPE 
as a marker for peritoneal large pore dysfunction [11, 12, 30]. Under this perspective, PPE could be a 
marker of systemic endothelial dysfunction and inflammation akin, to a certain point, to proteinuria, 
rather than a pathogenic disorder itself. The observed association between PPE and CV disease at the start 
of dialysis [11, 14, 15, present study] supports this point of view. Overall, hypotheses contemplating PPE 
either as a marker of vascular disease or as a pathogenic disorder are not mutually exclusive, and may 
help explain the association between PPE and the outcome of PD patients.  
 
According to our data, PPE during the baseline PET is a more accurate predictor of outcome than PPE 
calculated from 24-hour dialysate collections. The PET permits a standard, reproducible estimation of 
peritoneal protein transport, as opposed to assessment from 24- hour dialysate collections, which may be 
biased by other factors unrelated to the prognosis of PD patients. For instance, inconsistencies in the 
collection and management of samples are more likely during 24-hour collections. Patients treated with 
automated PD may be particularly prone to incorrect sampling, which may help to explain the poorer 
correlation between the scrutinized tests observed in this subgroup (fig. 1). Otherwise, a previous study 
from our group [19] showed that the results of the 2.27 and 3.86% PET are comparable in relation to PPE, 
provided total PPE or PCl, rather than dialysate protein concentrations, are used for analysis. We also 
demonstrated that the pirogalol red method for estimating dialysate protein levels is not affected by 
dialysate glucose concentration or storage [19], although this needs to be tested for the other individual 
methods. Biases induced by storage of spent dialysate should be more of a concern during 24-hour, rather 
than in PET, dialysate collections. On the other hand, the PD schedule may influence 24-hour PPE, 
although there is some controversy about the real impact of this factor, fed by a paucity of quality studies 
assessing this question [19, 21, 22, 31, 32]. Overall, PET-PPE may be a more specific marker of 
peritoneal large-pore dysfunction than 24-hour PPE. The latter should be less disadvantageous at the time 
of establishing correlations with PPE-induced malnutrition and metabolic disorders because it estimates 
the real amount of PPE.  
 
PET-PPE/PCl was able to predict different outcomes of our patients. The background hypothesis 
could suggest a primary CV impact on PPE, but the correlation with infectious mortality and peritonitis 
was clear (table 6). A previous study [11] reported a significant infectious mortality among PD patients 
with higher large-pore areas. This finding should not be unexpected because, as a whole, a high PPE 
marks a poor general condition of PD patients. We have shown in a previous study [33] that general 
prognostic factors, such as older age, malnutrition, inflammation or a low glomerular filtration rate, 
portend a high risk of peritonitis-related mortality. The design of the present study does not permit the 
assessment of the specific roles played by PPE induced malnutrition or peritoneal depletion of 
immunoactive proteins on infectious morbidity and mortality of these patients.  
 
PET-PPE and PET-PCl were roughly equivalent at the time of predicting the outcome of PD patients, 
which should not represent a surprise given the expectedly tight correlation between both variables (r = 
0.94). We advocate PET-PPE over PET-PCl, both for theoretical and practical reasons. There are some 
limitations to the use of the a priori attractive concept of PCl in this setting. The term ‘total protein’ 
includes an array of substances with different peritoneal transport rates. Plotting dialysate versus serum 
total protein is, thus, conceptually misleading. An estimation using serum albumin as the reference value 
[15, present study] has been proposed by Haraldsson [20] , and is based on the idea that albumin is the 
main protein implicated in peritoneal transport. However, the applied correction factor is generic, which 
does not add precision to the estimation of PPE in individual patients. PCl of albumin may be a good 
alternative [11], but routine determination of dialysate albumin is generally less convenient than that of 
total protein. Moreover, the prognostic significance of the PCl of albumin and total protein may not be the 
same, and the former needs specific assessment. In our study, the use of PPE and albumin separately, 
rather than as a composite variable (PCl), permitted better mathematical models in the majority of cases 
(tables 5, 6). Overall, PET-PPE – in our opinion – is simple, easy to interpret and slightly more predictive 
than PET-PCl.  
 
The main strengths of this study are the good quality of the data base used for analysis and the 
consistency of the main results. The limitations include its retrospective nature and a limited statistical 
potency. The latter may underlie the relative inconsistency of multivariate models for some secondary 
outcomes (e.g. CV events), and limits our capacity to disclose some important questions. For instance, 
our data do not permit an analysis of the potential links between PPE, malnutrition and mortality because 
the prevalence of overt malnutrition was low (table 1).  
 
In summary, our study shows a definite correlation between baseline PPE during PD on one side and 
peritoneal transport characteristics and CV comorbidity on the other, as PPE represents an independent 
predictor of outcome of PD patients. Quantification of total dialysate protein content at the end of a 
standard PET is a reproducible and accurate estimator of PPE, and is seemingly more convenient than 24-
hour PPE. PET-PPE and PETPCl are essentially interchangeable for this purpose, although the former 
may offer some minor advantages, including simplicity. PPE during baseline PET sustains a strong 
independent association with later CV and infectious mortality, and shows a significant association with 
the risk of peritonitis. These data indicate that PPE should be monitored as a baseline comprehensive 
marker of outcome in PD patients.  
  
References 
1. Pollock CA, Cooper BA, Ibels LS, Kantzow E: Nutritional aspects of peritoneal dialysis; in Gokal R, Khanna R, 
Krediet RT, Nolph KD (eds.): Textbook of Peritoneal Dialysis. Dordrecht, Kluwer Assoc., 2000, pp 515–543. 
2. Robey C, Shreedhar K, Batuman V: Effects of chronic peritoneal dialysis on thyroid function tests. Am J Kidney 
Dis 1989; 13: 99–103. 
3. Culleton BF, Wilson PW: Thrombogenic risk factors for cardiovascular disease in dialysis patients. Semin Dial 
1999; 12: 117–125. 
4. Kim SB, Yang WS, Park JS: Role of hypoalbuminemia in the genesis of cardiovascular disease in dialysis 
patients. Perit Dial Int 1999; 19(Suppl 2):144–149. 
5. Burkart J: Metabolic consequences of peritoneal dialysis. Semin Dial 2004; 17: 498–504. 
6. Liu J, Rosner MH: Lipid abnormalities associated with end-stage renal disease. Semin Dial 2006; 19: 32–40. 
7. Heimbürger O, Waniewski J, Werynski A, Lindholm B: A quantitative description of solute and fluid transport 
during peritoneal dialysis. Kidney Int 1992; 41: 1320–1332. 
8. Rippe B: A three-pore model of peritoneal transport. Perit Dial Int 1993; 13(Suppl 2):35–38. 
9. Buis B, Koomen GCM, Imholz ALT, Struijk DG, Reddingius RE, Arisz L, Krediet RT: Effect of electric charge 
on the transperitoneal transport of plasma proteins during CPD. Nephrol Dial Transplant 1996; 11: 1113–1120. 
10. Devuyst O, Goffin E: Water and solute transport in peritoneal dialysis: models and clinical applications. Nephrol 
Dial Transplant 2008; 23: 2120–2123. 
11. Heaf JG, Sarac S, Afzal S: A high peritoneal large pore fluid flux causes hypoalbuminemia and is a risk factor for 
death in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20: 2194–2201. 
12. Rippe B, Venturoli D, Simonsen O, de Arteaga J: Fluid and electrolyte transport across the peritoneal membrane 
during CAPD according to the three-pore model. Perit Dial Int 2004; 24: 10–27. 
13. Szeto CC, Chow KM, Lam CWK, Cheung R, Kwan BCH, Chung KY, Leung CB, Li PKT: Peritoneal albumin 
excretion is a strong predictor of cardiovascular events in peritoneal dialysis patients: a prospective cohort study. 
Perit Dial Int 2005; 25: 445–452. 
14. Sanchez Villanueva R, Bajo A, del Peso G, Fernández Reyes MJ, González E, Romero S, Estrada P, Selgas R: 
Higher daily peritoneal protein clearance when initiating peritoneal dialysis is independently associated with 
peripheral artery disease: a possible new marker of systemic endothelial dysfunction? Nephrol Dial Transplant 
2009; 24: 1009–1014. 
15. Perl J, Huckvale K, Chellar M, John B, Davies SJ: Peritoneal protein clearance and not peritoneal membrane 
transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 
2009; 4: 1201–1206. 
16. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, Nielsen MP: Peritoneal equilibration 
test. Perit Dial Int 1987; 7: 138–148. 
17. Smit W, Van Dijk P, Langedijk M, Schouten N, Van der Berg N, Struijk D, Krediet R: Peritoneal function and 
assessment of reference values using a 3.86% glucose solution. Perit Dial Int 2003; 23: 440–449. 
18. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M: Kinetics of peritoneal protein loss during CAPD: I. Different 
characteristics for low and high molecular weight proteins. Kidney Int 1990; 37: 971–979. 
19. Gomes AM, Pérez Fontán M, Rodríguez-Carmona A, López-Muñiz A, Fernández M, Peteiro J, García-Falcón T: 
Peritoneal total protein transport assessed from peritoneal equilibration tests with different dialysate glucose 
concentrations. Perit Dial Int, in press. 
20. Haraldsson B: Assessing the peritoneal dialysis capacities of individual patients. Kidney Int 1995; 47: 1187–
1198. 
21. Clerbaux G, Francart J, Wallemacq P, Robert A, Goffin E: Evaluation of peritoneal transport properties at onset 
of peritoneal dialysis and longitudinal follow-up. Nephrol Dial Transplant 2006; 21: 1032–1039. 
22. Blake PG, Flowerdew G, Blake RM, Oreopoulos DG: Serum albumin in patients on CAPD – predictions and 
correlations with outcomes. J Am Soc Nephrol 1993; 3: 1501–1507. 
23. Wang T, Heimbürger O, Cheng HH, Bergström J, Lindholm B: Does a high peritoneal transport rate reflect a 
state of chronic inflammation? Perit Dial Int 1999; 19: 17–22. 
24. Kang DH, Yoon KI, Choi KB, Lee R, Lee HY, Han DS, Cho EY, Lee JH: Relationship of peritoneal membrane 
transport characteristics to the nutritional status in CAPD patients. Nephrol Dial Transplant 1999; 14: 1715–1722. 
25. Chung SH, Chu WS, Lee HA, Kim YH, Lee IS, Lindholm B, Lee HB: Peritoneal transport characteristics, 
comorbid diseases and survival in CAPD patients. Perit Dial Int 2000; 20: 541–547. 
26. Margetts PJ, McMullin JP, Rabbat CG, Churchill DN: Peritoneal membrane transport and hypoalbuminemia: 
cause or effect? Perit Dial Int 2000; 20: 14–18. 
27. Cueto-Manzano AM, Correa-Rotter R: Is high peritoneal transport rate an independent risk factor for CAPD 
mortality? Kidney Int 2000; 57: 314–320. 
28. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimbürger O, Lindholm B: Chronic inflammation in peritoneal 
dialysis: the search for the holy grail?. Perit Dial Int 2004; 24: 327–339. 
29. Reyes MJ, Bajo MA, Hevia C, del Peso G, Ros S, de Miguel AG, Cirugeda A, Castro MJ, Sanchez Tomero JA, 
Selgas R: Inherent high peritoneal transport and ultrafiltration deficiency: their mid-term clinical relevance. 
Nephrol, Dial Transplant 2007; 22: 218–223. 
30. van Biesen W, van der Tol A, Veys N, Dequidt C, Vijt D, Lameire N, Vanholder R: The personal dialysis 
capacity test is superior to the peritoneal equilibration test to discriminate inflammation as the cause of fast 
transport status in peritoneal dialysis patients. Clin J Am Soc Nephrol 2006; 1: 269–274. 
31. Kathuria P, Moore HL, Khanna R, Twardowski ZJ, Goel S, Nolph KD: Effect of dialysis modality and membrane 
transport characteristics on dialysate protein losses of patients on peritoneal dialysis. Perit Dial Int 1997: 17: 449–
454. 
32. Westra WM, Kople JD, Krediet RT, Appell M, Mehrotra R: Dietary protein requirements and dialysate protein 
losses in chronic peritoneal dialysis patients. Perit Dial Int 2007; 27: 192–195. 
33. Pérez Fontán M, Rodríguez-Carmona A, García Naveiro R, Rosales M, Villaverde P, Valdés F: Peritonitis-related 
mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2005; 25: 274–284. 
34. Cooper S, Iliescu EA, Morton AR: The relationship between dialysate protein loss and membrane transport status 
in peritoneal dialysis patients. Adv Perit Dial 2001; 17: 244–247. 
35. Oh KH, Moon JY, Oh J, Kim SG, Hwang YH, Kim S, Lee JS, Ahn C: Baseline peritoneal solute transport rate is 
not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis 
patients. Nephrol Dial Transplant 2008; 23: 2356–2364. 
